{"transactions":[{"id":826284,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T23:36:20.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":50971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-26-036319","document":"tm2610129-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036319/tm2610129-3_4seq1.xml","form_type":"4"}},{"id":826283,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:36:20.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":104.79,"value":1571850.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":84115,"source":{"system":"sec-edgar","filing":"0001104659-26-036319","document":"tm2610129-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036319/tm2610129-3_4seq1.xml","form_type":"4"}},{"id":826282,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-27T23:36:20.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":8.04,"value":120600.0,"ownership":{"direct":true},"balance_after":99115,"source":{"system":"sec-edgar","filing":"0001104659-26-036319","document":"tm2610129-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926036319/tm2610129-3_4seq1.xml","form_type":"4"}},{"id":929900,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":65971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929899,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":70971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929898,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":82,"value":410000.0,"ownership":{"direct":true},"balance_after":84115,"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929897,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":8.04,"value":40200.0,"ownership":{"direct":true},"balance_after":89115,"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929896,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":82.28,"value":411400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.14 to $82.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":84115,"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929895,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":8.04,"value":40200.0,"ownership":{"direct":true},"balance_after":89115,"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":929894,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-28T02:19:50.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":13151,"price":82.42,"value":1083905.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.665 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":84115,"source":{"system":"sec-edgar","filing":"0001104659-26-007127","document":"tm264253-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926007127/tm264253-1_4seq1.xml","form_type":"4"}},{"id":934122,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-21T22:17:42.000Z","date":"2026-01-20","kind":"sale","planned":false,"acquired":false,"shares":9514,"price":82.48,"value":784714.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":97266,"source":{"system":"sec-edgar","filing":"0001104659-26-005443","document":"tm263774-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926005443/tm263774-3_4seq1.xml","form_type":"4"}},{"id":946151,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T00:35:56.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":32000,"derivative":{"exercise_price":87.18,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-26-001471","document":"tm262304-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926001471/tm262304-1_4seq1.xml","form_type":"4"}},{"id":946150,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-07T00:35:56.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":25600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":106780,"source":{"system":"sec-edgar","filing":"0001104659-26-001471","document":"tm262304-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926001471/tm262304-1_4seq1.xml","form_type":"4"}},{"id":993612,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-19T21:01:18.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":2712,"price":84.77,"value":229896.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":81180,"source":{"system":"sec-edgar","filing":"0001104659-25-114082","document":"tm2531619-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925114082/tm2531619-1_4seq1.xml","form_type":"4"}},{"id":1114791,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:40:40.000Z","date":"2025-06-10","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":75971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-25-058597","document":"tm2517775-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925058597/tm2517775-1_4seq1.xml","form_type":"4"}},{"id":1114790,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:40:40.000Z","date":"2025-06-09","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":85971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-25-058597","document":"tm2517775-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925058597/tm2517775-1_4seq1.xml","form_type":"4"}},{"id":1114789,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:40:40.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":57.03,"value":570300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.665 to $57.48. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":83892,"source":{"system":"sec-edgar","filing":"0001104659-25-058597","document":"tm2517775-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925058597/tm2517775-1_4seq1.xml","form_type":"4"}},{"id":1114788,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:40:40.000Z","date":"2025-06-10","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":8.04,"value":80400.0,"ownership":{"direct":true},"balance_after":93892,"source":{"system":"sec-edgar","filing":"0001104659-25-058597","document":"tm2517775-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925058597/tm2517775-1_4seq1.xml","form_type":"4"}},{"id":1114787,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:40:40.000Z","date":"2025-06-09","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":55.51,"value":555100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.18 to $55.75. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":83892,"source":{"system":"sec-edgar","filing":"0001104659-25-058597","document":"tm2517775-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925058597/tm2517775-1_4seq1.xml","form_type":"4"}},{"id":1114786,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:40:40.000Z","date":"2025-06-09","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":8.04,"value":80400.0,"ownership":{"direct":true},"balance_after":93892,"source":{"system":"sec-edgar","filing":"0001104659-25-058597","document":"tm2517775-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925058597/tm2517775-1_4seq1.xml","form_type":"4"}},{"id":1205595,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T22:21:44.000Z","date":"2025-03-13","kind":"exercise","planned":false,"acquired":false,"shares":2077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":47785,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":2077},"source":{"system":"sec-edgar","filing":"0001104659-25-024063","document":"tm259281-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925024063/tm259281-2_4seq1.xml","form_type":"4"}},{"id":1205594,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-14T22:21:44.000Z","date":"2025-03-13","kind":"exercise","planned":false,"acquired":false,"shares":28437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":69063,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":28437},"source":{"system":"sec-edgar","filing":"0001104659-25-024063","document":"tm259281-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925024063/tm259281-2_4seq1.xml","form_type":"4"}},{"id":1205593,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-14T22:21:44.000Z","date":"2025-03-13","kind":"sale","planned":false,"acquired":false,"shares":30514,"price":55.74,"value":1700850.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.245 to $56.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":83892,"source":{"system":"sec-edgar","filing":"0001104659-25-024063","document":"tm259281-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925024063/tm259281-2_4seq1.xml","form_type":"4"}},{"id":1205592,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-14T22:21:44.000Z","date":"2025-03-13","kind":"exercise","planned":false,"acquired":true,"shares":2077,"price":38.98,"value":80961.46,"ownership":{"direct":true},"balance_after":114406,"source":{"system":"sec-edgar","filing":"0001104659-25-024063","document":"tm259281-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925024063/tm259281-2_4seq1.xml","form_type":"4"}},{"id":1205591,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-14T22:21:44.000Z","date":"2025-03-13","kind":"exercise","planned":false,"acquired":true,"shares":28437,"price":23.42,"value":665994.54,"ownership":{"direct":true},"balance_after":112329,"source":{"system":"sec-edgar","filing":"0001104659-25-024063","document":"tm259281-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925024063/tm259281-2_4seq1.xml","form_type":"4"}},{"id":1299927,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-17T22:47:00.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":3252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":83892,"source":{"system":"sec-edgar","filing":"0001104659-25-004571","document":"tm253633-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925004571/tm253633-3_4seq1.xml","form_type":"4"}},{"id":1299926,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-17T22:47:00.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":87144,"source":{"system":"sec-edgar","filing":"0001104659-25-004571","document":"tm253633-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925004571/tm253633-3_4seq1.xml","form_type":"4"}},{"id":1310226,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T23:06:01.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":49862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":49862,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":49862},"source":{"system":"sec-edgar","filing":"0001104659-25-001427","document":"tm252003-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925001427/tm252003-2_4seq1.xml","form_type":"4"}},{"id":1310225,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T23:06:01.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":41088,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":87532,"source":{"system":"sec-edgar","filing":"0001104659-25-001427","document":"tm252003-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925001427/tm252003-2_4seq1.xml","form_type":"4"}},{"id":1349158,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-27","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":95971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349157,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-27","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":111971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349156,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":false,"shares":5529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":121971,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":5529},"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349155,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-27","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":44.83,"value":717280.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.50 to $44.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":46444,"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349154,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-27","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":8.04,"value":128640.0,"ownership":{"direct":true},"balance_after":62444,"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349153,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-27","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":44.5,"value":445000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $43.80 to $44.92. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":46444,"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349152,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-27","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":8.04,"value":80400.0,"ownership":{"direct":true},"balance_after":56444,"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349151,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":5529,"price":45.6,"value":252122.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.94. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":46444,"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1349150,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:11:13.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":true,"shares":5529,"price":8.04,"value":44453.16,"ownership":{"direct":true},"balance_after":51973,"source":{"system":"sec-edgar","filing":"0001104659-24-123809","document":"tm2429758-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123809/tm2429758-3_4seq1.xml","form_type":"4"}},{"id":1358827,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-19T23:49:11.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":1906,"price":40.98,"value":78107.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":46444,"source":{"system":"sec-edgar","filing":"0001104659-24-120670","document":"tm2428939-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924120670/tm2428939-1_4seq1.xml","form_type":"4"}},{"id":1676201,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-19T01:00:41.000Z","date":"2024-01-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":427,"price":24.63,"value":10517.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 1,041 restricted stock units on January 15, 2024."}],"balance_after":48350,"source":{"system":"sec-edgar","filing":"0001104659-24-004901","document":"tm243616-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924004901/tm243616-2_4seq1.xml","form_type":"4"}},{"id":1687503,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T01:09:17.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":97500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":97500,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0001104659-24-001490","document":"tm241954-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924001490/tm241954-2_4seq1.xml","form_type":"4"}},{"id":1687502,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-05T01:09:17.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":48777,"source":{"system":"sec-edgar","filing":"0001104659-24-001490","document":"tm241954-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924001490/tm241954-2_4seq1.xml","form_type":"4"}},{"id":1687501,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-05T01:09:17.000Z","date":"2023-11-15","kind":"sale","planned":false,"acquired":false,"shares":1848,"price":16.24,"value":30011.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":22527,"source":{"system":"sec-edgar","filing":"0001104659-24-001490","document":"tm241954-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924001490/tm241954-2_4seq1.xml","form_type":"4"}},{"id":2052249,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-19T00:51:01.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":18750,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001104659-23-004722","document":"tm233829-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923004722/tm233829-5_4seq1.xml","form_type":"4"}},{"id":2052248,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-19T00:51:01.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on January 15, 2024, 2025 and 2026."}],"balance_after":24375,"source":{"system":"sec-edgar","filing":"0001104659-23-004722","document":"tm233829-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923004722/tm233829-5_4seq1.xml","form_type":"4"}},{"id":2111921,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-17T23:22:05.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which will vest on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":127500,"derivative":{"exercise_price":8.04,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001104659-22-119971","document":"tm2230775-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119971/tm2230775-2_4seq1.xml","form_type":"4"}},{"id":2111920,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-11-17T23:22:05.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":21250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in shares of the Issuer's common stock that will vest in four annual installments on November 15, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":21250,"source":{"system":"sec-edgar","filing":"0001104659-22-119971","document":"tm2230775-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119971/tm2230775-2_4seq1.xml","form_type":"4"}},{"id":2136906,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:07:03.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":6750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":6.12,"underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0000899243-22-033655","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1398940/000089924322033655/doc4.xml","form_type":"4"}},{"id":2136905,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:07:03.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":16750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":11.97,"underlying":"Common Stock","underlying_shares":16750},"source":{"system":"sec-edgar","filing":"0000899243-22-033655","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398940/000089924322033655/doc4.xml","form_type":"4"}},{"id":2136904,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-14T16:07:03.000Z","date":"2022-10-14","kind":"other","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398940/000089924322033655/doc4.xml","form_type":"4"}},{"id":2237363,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T17:30:57.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 8, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":6750,"derivative":{"exercise_price":6.12,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0000899243-22-021658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398940/000089924322021658/doc4.xml","form_type":"4"}},{"id":2237362,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T17:30:57.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-22-021658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398940/000089924322021658/doc4.xml","form_type":"4"}},{"id":2347284,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2022-03-08T00:20:36.000Z","date":"2022-03-05","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date."}],"balance_after":37500,"derivative":{"expiration_date":"2025-03-05","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-016853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122016853/doc4.xml","form_type":"4"}},{"id":2347283,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2022-03-08T00:20:36.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date."}],"balance_after":39000,"derivative":{"expiration_date":"2026-03-04","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001209191-22-016853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122016853/doc4.xml","form_type":"4"}},{"id":2347282,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2022-03-08T00:20:36.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":52000,"derivative":{"exercise_price":8.17,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001209191-22-016853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122016853/doc4.xml","form_type":"4"}},{"id":2347281,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-08T00:20:36.000Z","date":"2022-03-05","kind":"tax_withholding","acquired":false,"shares":4355,"price":8.17,"value":35580.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":37736,"source":{"system":"sec-edgar","filing":"0001209191-22-016853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122016853/doc4.xml","form_type":"4"}},{"id":2347280,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-08T00:20:36.000Z","date":"2022-03-05","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."}],"balance_after":42091,"source":{"system":"sec-edgar","filing":"0001209191-22-016853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122016853/doc4.xml","form_type":"4"}},{"id":2418903,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2022-02-02T01:36:09.000Z","date":"2022-01-29","kind":"exercise","acquired":false,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date."}],"balance_after":10500,"derivative":{"expiration_date":"2025-01-29","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001209191-22-006127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122006127/doc4.xml","form_type":"4"}},{"id":2418902,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-02T01:36:09.000Z","date":"2022-01-29","kind":"tax_withholding","acquired":false,"shares":2151,"price":10.39,"value":22348.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":29591,"source":{"system":"sec-edgar","filing":"0001209191-22-006127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122006127/doc4.xml","form_type":"4"}},{"id":2418901,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-02T01:36:09.000Z","date":"2022-01-29","kind":"exercise","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":31742,"source":{"system":"sec-edgar","filing":"0001209191-22-006127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919122006127/doc4.xml","form_type":"4"}},{"id":2435719,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-13T16:22:15.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":16750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33.3% of the shares subject to the stock option will vest on January 12, 2023, and the remainder of the shares vest in equal monthly installments for a period of 24 months thereafter."}],"balance_after":16750,"derivative":{"exercise_price":11.97,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":16750},"source":{"system":"sec-edgar","filing":"0000899243-22-001901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398940/000089924322001901/doc4.xml","form_type":"4"}},{"id":2435718,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T16:22:15.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0000899243-22-001901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398940/000089924322001901/doc4.xml","form_type":"4"}},{"id":2557385,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2021-09-28T22:57:07.000Z","date":"2021-09-24","kind":"exercise","acquired":false,"shares":8609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"expiration_date":"2021-09-26","underlying":"Common Stock","underlying_shares":8609},"source":{"system":"sec-edgar","filing":"0001209191-21-057980","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121057980/doc4.xml","form_type":"4"}},{"id":2557384,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-28T22:57:07.000Z","date":"2021-09-24","kind":"tax_withholding","acquired":false,"shares":2976,"price":19.23,"value":57228.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":26492,"source":{"system":"sec-edgar","filing":"0001209191-21-057980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121057980/doc4.xml","form_type":"4"}},{"id":2557383,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-28T22:57:07.000Z","date":"2021-09-24","kind":"exercise","acquired":true,"shares":8609,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29468,"source":{"system":"sec-edgar","filing":"0001209191-21-057980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121057980/doc4.xml","form_type":"4"}},{"id":2802683,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2021-03-08T22:20:15.000Z","date":"2021-03-05","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date."}],"balance_after":50000,"derivative":{"expiration_date":"2025-03-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-018622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121018622/doc4.xml","form_type":"4"}},{"id":2802682,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2021-03-08T22:20:15.000Z","date":"2021-03-05","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning on April 5, 2021, with 100% of the total shares vested and exercisable on March 5, 2025, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":21.11,"expiration_date":"2031-03-04","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-018622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121018622/doc4.xml","form_type":"4"}},{"id":2888321,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2021-02-01T22:55:54.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date."}],"balance_after":15750,"derivative":{"expiration_date":"2024-01-29","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001209191-21-006558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121006558/doc4.xml","form_type":"4"}},{"id":2888320,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-01T22:55:54.000Z","date":"2021-01-29","kind":"tax_withholding","acquired":false,"shares":2107,"price":22.15,"value":46670.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":20859,"source":{"system":"sec-edgar","filing":"0001209191-21-006558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121006558/doc4.xml","form_type":"4"}},{"id":2888319,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-01T22:55:54.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22966,"source":{"system":"sec-edgar","filing":"0001209191-21-006558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919121006558/doc4.xml","form_type":"4"}},{"id":3021578,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2020-09-28T21:56:15.000Z","date":"2020-09-25","kind":"exercise","acquired":false,"shares":8609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date."}],"balance_after":8609,"derivative":{"expiration_date":"2021-09-26","underlying":"Common Stock","underlying_shares":8609},"source":{"system":"sec-edgar","filing":"0001209191-20-052247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919120052247/doc4.xml","form_type":"4"}},{"id":3021577,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-09-28T21:56:15.000Z","date":"2020-09-25","kind":"tax_withholding","acquired":false,"shares":2976,"price":10.3,"value":30652.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":17716,"source":{"system":"sec-edgar","filing":"0001209191-20-052247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919120052247/doc4.xml","form_type":"4"}},{"id":3021576,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-09-28T21:56:15.000Z","date":"2020-09-25","kind":"exercise","acquired":true,"shares":8609,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20692,"source":{"system":"sec-edgar","filing":"0001209191-20-052247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919120052247/doc4.xml","form_type":"4"}},{"id":3148540,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-14T21:27:49.000Z","date":"2020-05-14","kind":"purchase","acquired":true,"shares":6451,"price":7.75,"value":49995.25,"ownership":{"direct":true},"balance_after":12083,"source":{"system":"sec-edgar","filing":"0001209191-20-029244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919120029244/doc4.xml","form_type":"4"}},{"id":3296371,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2020-01-31T22:18:51.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date."}],"balance_after":21000,"derivative":{"expiration_date":"2024-01-29","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-20-005812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919120005812/doc4.xml","form_type":"4"}},{"id":3296370,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2020-01-31T22:18:51.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":47500,"derivative":{"exercise_price":10.09,"expiration_date":"2030-01-29","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001209191-20-005812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919120005812/doc4.xml","form_type":"4"}},{"id":3404242,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2019-09-30T21:25:06.000Z","date":"2019-09-26","kind":"exercise","acquired":false,"shares":8608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date."}],"balance_after":17218,"derivative":{"expiration_date":"2021-09-26","underlying":"Common Stock","underlying_shares":8608},"source":{"system":"sec-edgar","filing":"0001209191-19-051122","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919119051122/doc4.xml","form_type":"4"}},{"id":3404241,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-09-30T21:25:06.000Z","date":"2019-09-26","kind":"tax_withholding","acquired":false,"shares":2976,"price":9.74,"value":28986.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person."}],"balance_after":5632,"source":{"system":"sec-edgar","filing":"0001209191-19-051122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919119051122/doc4.xml","form_type":"4"}},{"id":3404240,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-09-30T21:25:06.000Z","date":"2019-09-26","kind":"exercise","acquired":true,"shares":8608,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8608,"source":{"system":"sec-edgar","filing":"0001209191-19-051122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919119051122/doc4.xml","form_type":"4"}},{"id":3681039,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2019-01-31T22:09:47.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":47500,"derivative":{"exercise_price":10.45,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001209191-19-006204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919119006204/doc4.xml","form_type":"4"}},{"id":3806430,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2018-09-27T22:03:14.000Z","date":"2018-09-26","kind":"grant","acquired":true,"shares":25826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date."}],"balance_after":25826,"derivative":{"expiration_date":"2021-09-25","underlying":"Common Stock","underlying_shares":25826},"source":{"system":"sec-edgar","filing":"0001209191-18-052491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919118052491/doc4.xml","form_type":"4"}},{"id":3806429,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":55589,"kind":"person","name":"MOLINA ARTURO MD","position":1,"cik":"0001398940","reported_name":"MOLINA ARTURO MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2018-09-27T22:03:14.000Z","date":"2018-09-26","kind":"grant","acquired":true,"shares":154958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":154958,"derivative":{"exercise_price":15,"expiration_date":"2028-09-25","underlying":"Common Stock","underlying_shares":154958},"source":{"system":"sec-edgar","filing":"0001209191-18-052491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000120919118052491/doc4.xml","form_type":"4"}}]}